

2010 Meeting Recap

25th Annual Meeting and Associated Programs September 30-October 4, 2010 Bethesda, MD & Washington, D.C.



Record Breaking Attendance!



For a second straight year, iSBTc had a record number of delegates attend the iSBTc Annual Meeting & Associated Programs. This increased attendance, coupled with the exciting scientific breakthroughs presented through oral and poster presentations, unmatched networking opportunities, and 25th Anniversary celebration made for one of the most successful iSBTc meetings on record.

Stay tuned to the iSBTc website for program summaries, speakers slides, and photos in the coming month.

Major NIH Announcement Made at iSBTc Meeting

At a special session during the iSBTc 25th Annual Meeting, **William Merritt**, **PhD** of the National Cancer Institute treated attendees to the first public announcement of the recipient of the grant that will fund the Central Operations and Statistical Office for the NIH sponsored Cancer Immunotherapy Trials Network (CITN) a national, cooperative research program. iSBTc Member, **Martin "Mac" Cheever, MD**, of the University of Washington, Fred Hutchinson Cancer Research Center was identified as the Principal Investigator with Members **Mary L. "Nora" Disis, MD** and **Kim Margolin, MD** as co-investigators. As Dr. Merrit noted, "The goal of the CITN will be to design, develop and conduct trials not otherwise possible, but with broad input and appeal for the immunotherapy community. "



Martin A. "Mac" Cheever, MD

Click here to read iSBTc's story about the CITN Announcement.

Collaborations Summit Hosted by iSBTc

Representatives from nine domestic and international associations were welcomed by iSBTc for a Collaboration Summit in conjunction with the Annual Meeting on October 1. This meeting of associations interested in promoting research and translation of cancer immunotherapy was organized by iSBTc in an effort to facilitate effective collaboration to accelerate delivery of new immunotherapies to patients with cancer throughout the world. Groups attending the Summit committed to further discussions and collaborative projects in the future. Stay tuned!

25th Anniversary Celebrated with Special Recognition Awards





iSBTc celebrated its 25 years of guiding cancer immunotherapy / biological therapy from bench to bedside with a grand reception held at the Smithsonian National Museum of Natural History. Included in the reception was a special awards ceremony recognizing individual leaders and scientific teams for their outstanding contributions to the field and the Society.

iSBTc "Team Science" Awards were presented to six groups representing over 100 people for fostering success in the field of cancer immunotherapy / biological therapy through the long-standing and continued collaborative contributions of team members. Additionally, six individuals were recognized with iSBTc Exceptional Service Awards for their distinguished leadership, continued contribution, and consummate dedication which fostered the growth and success of iSBTc over the past 25 years. Watch your email and the iSBTc website for more detailed profiles and photos of the award recipients.

iSBTc Changes to SITC

At the Membership Business Meeting on October 2, iSBTc Members officially accepted a bylaw revision to change the name of the Society to the **Society for Immunotherapy of Cancer** (SITC). This change was made to better align the name and function of the society with the mission of the group, which remains to improve cancer patient outcomes by advancing the science, development and application of immunotherapy/biological therapy.



Scientific Community Mourns Loss of Alexander Fefer



iSBTc is saddened by the passing of Alexander Fefer, MD of the University of Washington, Fred Hutchinson Cancer Research Center (UW/FHCRC). Dr. Fefer was a pioneer in cancer immunotherapy and bone marrow transplantation. At the time of his death, Dr. Fefer was attending the iSBTc 25th Annual Meeting to receive a "Team Science" Award together with UW/FHCRC colleagues for seminal work on adoptive T cell therapy and other T cell-based immunotherapies to treat cancer. Our condolences go to his family and all who had the opportunity to work with this remarkable scientist.


Positive Immunotherapy Trial Results Published During iSBTc Annual Meeting

Positive clinical trial results from two separate immunotherapy studies were published amidst the excitement of the 2010 iSBTc Annual Meeting, underscoring the rapid, promising growth in the field of cancer immunotherapy.

- Yu, AL. et al. Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma. *N Engl J Med* 2010; 363: 1324-1334 To view a summary, <u>click here.</u>
- Brody, JD, et al. In Situ Vaccination with a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study. JCO 2010; 28: 4324-4332 To view a summary, <u>click here</u>.

Share Your 2010 iSBTc Meeting Photos/Videos

Did you get some great photos or videos at the iSBTc 2010 Programs? Share them with us for possible use on the website and in print material. Email them to info@isbtc.org or contact the iSBTc office at 414-271-2456.



You have received this message because you have had previous contact with the International Society for Biological Therapy of Cancer. If you do not wish to be included in our mailing list, please forward this message to <u>info@isbtc.org</u> with "Remove" in the subject line.

International Society for Biological Therapy of Cancer 555 East Wells Street, Suite 1100 Milwaukee, Wisconsin 53202-3823 Phone: 414-271-2456 Email: <u>info@isbtc.org</u> ©2010 iSBTc All rights reserved